menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update

CAMBRIDGE, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present second quarter 2019 results and operational highlights in
Read More

Intellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Actions Relating to Key CRISPR/Cas9 Genome Editing Technology

New patent interference proceeding initated by the United States Patent and Trademark Office (USPTO) will determine if the University of California, University of Vienna and Emmanuelle Charpentier (UC Group) were first to invent the use of CRISPR/Cas9 in eukaryotic cells, which could result in up
Read More

Intellia Therapeutics to Participate at June Healthcare Investor Conferences

CAMBRIDGE, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in
Read More

Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer

CAMBRIDGE, Mass. , May 28, 2019 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc. , (NASDAQ:NTLA) has named Laura Sepp-Lorenzino , Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and
Read More

Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update

Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosis Expects to nominate first engineered cell therapy development candidate for treatment of acute myeloid
Read More

Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy

Intellia scientists advance CRISPR-mediated targeted gene insertion in non-human primates Achieved normal circulating human Factor IX protein levels in non-human primates using targeted gene insertion High rate and specificity of acute myeloid leukemia cell killing progressed using genome-edited,
Read More

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update

CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present first quarter 2019 results and operational highlights in
Read More

Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy

CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22 nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019 , in Washington, D.C.
Read More

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results

Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020 submission Engineered cell therapy platform will enable wholly owned development candidate for acute
Read More

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed Fred Cohen , M.D., D.Phil, F.A.C.P., to its board of
Read More
RSS FEEDS
PRINT PAGE